Frontiers in Neurology (Nov 2019)
Extracellular Vesicles Can Deliver Anti-inflammatory and Anti-scarring Activities of Mesenchymal Stromal Cells After Spinal Cord Injury
- Pasquale Romanelli,
- Pasquale Romanelli,
- Lara Bieler,
- Lara Bieler,
- Cornelia Scharler,
- Cornelia Scharler,
- Karin Pachler,
- Karin Pachler,
- Christina Kreutzer,
- Christina Kreutzer,
- Pia Zaunmair,
- Pia Zaunmair,
- Dominika Jakubecova,
- Dominika Jakubecova,
- Heike Mrowetz,
- Heike Mrowetz,
- Bruno Benedetti,
- Bruno Benedetti,
- Francisco J. Rivera,
- Francisco J. Rivera,
- Francisco J. Rivera,
- Francisco J. Rivera,
- Ludwig Aigner,
- Ludwig Aigner,
- Ludwig Aigner,
- Eva Rohde,
- Eva Rohde,
- Eva Rohde,
- Mario Gimona,
- Mario Gimona,
- Dirk Strunk,
- Dirk Strunk,
- Sebastien Couillard-Despres,
- Sebastien Couillard-Despres,
- Sebastien Couillard-Despres
Affiliations
- Pasquale Romanelli
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Pasquale Romanelli
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Lara Bieler
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Lara Bieler
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Cornelia Scharler
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Cornelia Scharler
- Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University, Salzburg, Austria
- Karin Pachler
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Karin Pachler
- GMP Laboratory, Paracelsus Medical University, Salzburg, Austria
- Christina Kreutzer
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Christina Kreutzer
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Pia Zaunmair
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Pia Zaunmair
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Dominika Jakubecova
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Dominika Jakubecova
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Heike Mrowetz
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Heike Mrowetz
- Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
- Bruno Benedetti
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Bruno Benedetti
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Francisco J. Rivera
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Francisco J. Rivera
- Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
- Francisco J. Rivera
- Laboratory of Stem Cells and Neuroregeneration, Faculty of Medicine, Institute of Anatomy, Histology and Pathology, Universidad Austral de Chile, Valdivia, Chile
- Francisco J. Rivera
- Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
- Ludwig Aigner
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Ludwig Aigner
- Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
- Ludwig Aigner
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Eva Rohde
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Eva Rohde
- GMP Laboratory, Paracelsus Medical University, Salzburg, Austria
- Eva Rohde
- University Department of Transfusion Medicine, University Clinic Salzburg Paracelsus Medical University, Salzburg, Austria
- Mario Gimona
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Mario Gimona
- GMP Laboratory, Paracelsus Medical University, Salzburg, Austria
- Dirk Strunk
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Dirk Strunk
- Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University, Salzburg, Austria
- Sebastien Couillard-Despres
- Institute of Experimental Neuroregeneration, Paracelsus Medical University, Salzburg, Austria
- Sebastien Couillard-Despres
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Salzburg, Austria
- Sebastien Couillard-Despres
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- DOI
- https://doi.org/10.3389/fneur.2019.01225
- Journal volume & issue
-
Vol. 10
Abstract
Spinal cord injury is characterized by initial neural tissue disruption that triggers secondary damage and extensive non-resolving inflammation, which aggravates loss of function and hinders recovery. The early onset of inflammation following traumatic spinal cord injury underscores the importance of acute intervention after the initial trauma. Injections of mesenchymal stromal cells (MSCs) can reduce inflammation following spinal cord injury. We asked if extracellular vesicles (EVs) can substitute the anti-inflammatory and anti-scarring activities of their parental MSCs in a rat model of contusion spinal cord injury. We report that MSC-EVs were as potent as the parental intact cells in reducing the level of neuroinflammation for up to 2 weeks post-injury. Acute application of EVs after spinal cord injury was shown to robustly decrease the expression of pro-inflammatory cytokines in the spinal cord parenchyma in the very early phase of secondary damage. Moreover, the anti-scarring impact of MSC-EVs was even more efficient than the parental cells. We therefore conclude that anti-inflammatory and anti-scarring activities of MSC application can be mediated by their secreted EVs. In light of their substantial safety and druggability advantages, EVs may have a high potential in early therapeutic treatment following traumatic spinal cord injury.
Keywords